fondaparinux and Endotoxemia

fondaparinux has been researched along with Endotoxemia* in 2 studies

Other Studies

2 other study(ies) available for fondaparinux and Endotoxemia

ArticleYear
Enoxaparin and fondaparinux attenuates endothelial damage in endotoxemic rats.
    The journal of trauma and acute care surgery, 2012, Volume: 72, Issue:1

    Prophylactic use of anticoagulants for septic patients in intensive care unit is a standard therapy for the prevention of venous thrombosis. Moreover, recent studies have demonstrated the anti-inflammatory effects of anticoagulants such as Factor Xa inhibitors and heparins. However, there have been no studies to examine the effects of fondaparinux and enoxaparin when applied in a sepsis model. Therefore, we examined the anti-inflammatory effects and bleeding events when these agents are applied in a lipopolysaccharide challenge model.. Wistar rats received lipopolysaccharides followed by a bolus infusion of fondaparinux, enoxaparin, or placebo. Microscopic observation of the mesenteric microcirculation for endothelial damage and measurement of bleeding area after vascular puncture was performed (n = 6 in each group). In another series, blood samples were taken, and blood cell counts, coagulation markers, and organ damage markers were measured (n = 6 in each).. Both leukocyte adherence to vascular endothelium and endothelial damage were reduced in fondaparinux and enoxaparin groups. The bleeding area was markedly increased in the fondaparinux group. Coagulation markers were maintained better in the enoxaparin group. Levels of organ damage markers were significantly suppressed in both fondaparinux and enoxaparin groups (p < 0.01, compared with control, each).. Fondaparinux and enoxaparin reduce organ dysfunction by decreasing endothelial damage. However, bleeding was more prominent in the fondaparinux group compared with the enoxaparin group at an equipotent dose for anti-Xa activity. Because the setting of this experiment is different from the clinical use, further study is required for the comparison of both pharmaceuticals.

    Topics: Animals; Anticoagulants; Endothelium, Vascular; Endotoxemia; Enoxaparin; Factor Xa Inhibitors; Fondaparinux; Hemorrhage; Leukocytes; Lipopolysaccharides; Male; Polysaccharides; Rats; Rats, Wistar

2012
A coagulation factor VII deficiency protects against acute inflammatory responses in mice.
    The Journal of pathology, 2006, Volume: 210, Issue:4

    Upregulation of the activated Factor VII (FVIIa)/Tissue Factor complex, downregulation of natural anticoagulation pathways, and inhibition of fibrinolysis, are major contributors to coagulopathies associated with acute inflammation. Provision of FVIIa, and consequent downstream coagulation-related proteases, also stimulates further inflammatory changes, which can result in disseminated intravascular coagulation. Thus, the potential protective effects in vivo of a genetic-based reduction in FVII levels have been investigated in a murine model of acute inflammation, namely lipopolysaccharide (LPS)-induced lethal endotoxaemia. Mice with a total FVII deficiency do not survive the neonatal period. Therefore mice expressing low levels of FVII (FVII(tTA/tTA)), producing sufficient amounts of FVII for survival (approximately 5% of wild-type (WT) FVII), were employed to investigate in vivo pathways involved in the crosstalk between coagulation, inflammation, and survival, consequent to administration of a lethal dose of LPS. The FVII(tTA/tTA) mice presented with reduced mortality, coagulation, and inflammatory responses in comparison with similarly treated WT mice after administration of LPS. The attenuated inflammatory responses in FVII(tTA/tTA) mice were associated with downregulation of Egr-1 signalling. Administration, in vivo, of specific inhibitors of FXa and thrombin demonstrated that the inflammatory responses were unaltered in WT mice, but further reduced in FVII(tTA/tTA) mice. Therefore, a FVII deficiency enhances survival from lethal endotoxaemia both through attenuation of inflammatory responses that result directly from reduced FVIIa levels, and, indirectly, from downregulation of coagulation proteases downstream of the FVII-dependent cascade.

    Topics: Ancrod; Animals; Anticoagulants; Antithrombin III; Biomarkers; Blood Coagulation; Disease Models, Animal; Down-Regulation; Early Growth Response Protein 1; Endotoxemia; Factor VII Deficiency; Factor Xa; Fibrinogen; Fondaparinux; Hirudins; Lipopolysaccharides; Male; Mice; Mice, Inbred C57BL; Neutrophils; Peptide Hydrolases; Polysaccharides; Recombinant Proteins; Signal Transduction; Thrombin

2006